Multi-Therapeutic Platform
-
MNC* - High MNC collection efficiency with low platelet loss, flexible controls allow tailoring of MNC settings for targeted cell content based upon clinical need
-
TPE - High plasma removal efficiency, accurate fluid balance control with real-time volume measurement and automatic bag switching for replacement fluid
-
RBCx - Precision red cell removal for Exchange, Depletion/Exchange, and Depletion procedures with low extracorporeal volume (160 mL)
-
ECP** - The ECP protocol is an expanded indication for the Amicus Separator, utilizing Amicus MNC collection technology and the Phelix Photoactivation Device
-
Platelets* - High efficiency platelet collection with options for concurrent plasma, RBC collection and automatic PAS capability
* Platelets and MNC are a collection and not a therapeutic indication.
** The Amicus System for ECP is approved by Health Canada for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment (license #112267).